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Introduction: Anti-tuberculosis drug-induced cutaneous leukocytoclastic vasculitis has been rarely reported. To the
best of our knowledge, this is the first reported case of annular leukocytoclastic vasculitis associated with
anti-tuberculosis drug administration.
Case presentation: We report a case of annular leukocytoclastic vasculitis induced by anti-tuberculosis medication.
A 62-year-old Thai man presented to our facility with a generalized exanthematous rash on his trunk and
extremities that resolved shortly afterwards. Subsequently, he developed multiple, erythematous-to-purplish,
non-blanchable macules and papules with an annular arrangement on his extremities. The skin rash occurred after
two weeks of anti-tuberculosis medication. The histopathology of the purpuric skin lesion was consistent with
leukocytoclastic vasculitis. The skin lesion improved after discontinuation of the anti-tuberculosis drugs and
treatment with oral antihistamine and topical corticosteroid drugs. Streptomycin, ethambutol and ofloxacin were
administered as second-line anti-tuberculosis therapy during his hospitalization. No adverse reactions were
observed.
Conclusions: Leukocytoclastic vasculitis should be considered in the differential diagnosis of annular
non-blanchable macules and papules. Although rare, anti-tuberculosis drugs should be considered potential causes
of drug-induced annular leukocytoclastic vasculitis.Introduction
Leukocytoclastic vasculitis (LCV) is a histologically
defined condition characterized by necrotizing inflam-
mation around small dermal blood vessels, composed
mainly of neutrophils and their debris. The usual presen-
tation of LCV is polymorphous, with findings such as
purpuric papules, urticaria and ulceration. An annular
appearance of LCV is quite rare. Causes of LCV include
drug reactions, malignancies, connective tissue diseases,
infections and idiopathy [1,2]. An estimated 20 percent
to 30 percent of all vasculitis cases are attributed to drug
reactions. LCV has rarely been reported in association
with anti-tuberculosis drugs [3]. We report an unusual
clinical presentation of LCV following treatment with
anti-tuberculosis drugs.* Correspondence: kumutnart@hotmail.com
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A 62-year-old Thai man presented to our facility with a
generalized erythematous maculopapular rash on his
trunk and extremities. Our patient had been diagnosed
as having pulmonary tuberculosis two weeks earlier. He
had long-standing hypertension and diabetes mellitus;
his treatment for this included daily amlodipine 5mg,
metformin 500mg and glipizide 5mg daily. When tubercu-
losis was diagnosed, anti-tuberculosis therapy of isoniazid
300mg, rifampicin 450mg and ethambutol 800mg daily
was administered. After two weeks of anti-tuberculosis
medication, a generalized exanthematous rash appeared on
his trunk and extremities (Figure 1). All anti-tuberculosis
drugs were stopped after his admission due to a clinical
suspicion of drug-induced adverse cutaneous reactions.
The exanthematous rash resolved within three days of
admission, leaving post-inflammatory hyperpigmentation.
One day later, multiple well-defined, non-blanchable,
erythematous-to-purplish macules and papules, some of
which showed an annular arrangement, were noticedentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Generalized exanthematous rash on the trunk and
extremities of our patient.
Figure 2 Multiple, well-defined, non-blanchable, erythematous
macules and papules in an annular arrangement.
Figure 3 Histology of a purpuric annular lesion on our
patient’s leg.
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of systems was unremarkable.
Laboratory study findings were as follows: leukocytes,
12.8×103 cells/mm3 (neutrophils 86 percent, lympho-
cytes 9 percent, monocytes 2 percent, eosinophils 2 per-
cent, basophils 1 percent); hemoglobin, 7.9g/dL; platelet
count, 215×103 cells/mm3; creatinine, 1.2mg/dL; aspar-
tate aminotransferase, 31U/L; alanine aminotransferase,
34U/L; alkaline phosphatase, 582U/L; γ-glutamyl trans-
ferase, 393U/L; total bilirubin, 9.6mg/dL; direct bilirubin,
8.4mg/dL; hepatitis B surface antigen, anti-hepatitis C
virus and anti-human immunodeficiency virus (HIV) test
results were all negative. Anti-nuclear antibody and anti-
neutrophil cytoplasmic antibody test results were also
negative. Urine analysis results showed no evidence of
proteinuria or hematuria. The findings from an abdom-
inal ultrasound were unremarkable. A skin biopsy from
a purpuric annular lesion on his leg showed peri-vascular
and interstitial infiltration of neutrophils with extravasa-
tion of erythrocytes and fibrin deposition (Figure 3), char-
acteristic of LCV. A direct immunofluorescence (DIF)
study was positive for IgA, IgM and C3 along superficialdermal blood vessels, consistent with cutaneous small ves-
sel vasculitis (Figure 4). These findings were diagnostic for
annular LCV associated with anti-tuberculosis drugs and
drug-induced cholestasis. Our patient was treated with an
oral antihistamine and topical corticosteroids. The skin
eruption cleared within one week without hyperpigmenta-
tion and liver function test results returned to normal lim-
its three weeks after the anti-tuberculosis drugs were
Figure 4 Direct immunofluorescence revealed positive IgA, IgM
and C3 results along superficial dermal blood vessels.
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(800mg per day) and ofloxacin (400mg per day) were sub-
sequently administered as second-line anti-tuberculosis
therapy during the hospitalization. No adverse reactions
were observed. Therefore, he was subsequently treated
with ethambutol, ofloxacin and streptomycin without
recurrence of the skin rash.
Discussion
Cutaneous adverse reaction to anti-tuberculosis drugs
has been reported in up to 5 percent of patients treated.
Common cutaneous reactions include pruritus, urticaria,
maculopapular exanthems, fixed reaction and erythema
nodosum. Cutaneous LCV is a rare complication of anti-
tuberculosis medication [4]. The skin lesions typically
improve upon withdrawal of the medication. In a previous
study a case of rifampicin-induced and pyrazinamide-
induced LCV was reported, and it was suggested that
antibodies to drugs contribute to the pathogenesis of
vasculitis [5]. Cribier et al. first reported that some
patients with annular LCV constitute a distinctive sub-
type, with the following criteria [6]: (1) multiple attacks
over years with sudden onset and spontaneous regression
after seven to 10 days, (2) annular purpuric patches that
show centrifugal extension, (3) extension over the limbs
and trunk creating polycyclic lesions that clear leaving
mild hemosiderin deposition, (4) no extracutaneous symp-
toms and good general health, (5) histological changes of
LCV with mild vascular changes and intense polymorpho-
nuclear cell infiltration, and (6) complete clearance of all
lesions with dapsone (diamino-diphenyl sulfone). Our
patient’s case matches the second, third, fourth and fifth
criteria established by Cribier et al. Therefore, we cannot
completely classify our patient’s case as a distinct subtype
according to the criteria; however, the morphology of indi-
vidual lesions is compatible with LCV arranged in an
annular pattern, and as a result of this together with the
histologic and DIF findings diagnostic for LCV, we believethat our patient should be classified as having annular
LCV. The presence of extensive generalized erythematous
maculopapular rash on our patient’s trunk and extremities
might have obscured the initiation of the LCV lesions;
hence, onset of annular LCV was imprecise. The day
after resolution of the maculopapular rash, multiple,
well-defined, non-blanchable, erythematous-to-purplish
macules and papules, some of which showed an annular
arrangement, could be clearly noticeable.
Annular LCV is an uncommonly reported clinical vari-
ant of LCV. Annular LCV has been linked with systemic
diseases such as sarcoidosis, ulcerative colitis, cryoglobu-
linemia associated with hepatitis B, Sjögren’s syndrome,
cervical cancer, lymphoma, and monoclonal and poly-
clonal gammopathies [1,2]. Annular LCV has also been
linked to pregnancy, chlorzoxazone, sorafenib and amlo-
dipine besylate [7-10]. Amlodipine was not the culprit
drug for the development of LCV in our patient’s case
because he had been administered it for many years.
Moreover, his condition resolved despite continuation of
amlodipine. An extensive review of the literature revealed
no previous case reports of annular LCV associated with
anti-tuberculosis drugs.
Conclusions
In our patient’s case, the histology and resolution after
drug discontinuation suggest that anti-tuberculosis phar-
maceuticals may have been the offending drugs that
caused annular LCV. LCV should be considered in the
differential diagnosis of annular non-blanchable macules
and papules. Although rarely seen, anti-tuberculosis
drugs should be considered potential causes of drug-
induced annular LCV.
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